The goal of a new study published in Clinical Research in Cardiology was to analyze the impact of atrial fibrillation AF on prognosis in patients with cardiogenic shock CS complicating acute myocardial infarction AMI . In this sub study of the IABP SHOCK II trial patients were grouped according to the presence or absence of AF. The primary endpoint was all cause mortality at 30 day follow up. While secondary endpoints included all cause mortality recurrent myocardial infarction repeat revascularization and stroke at 12 months. The results revealed documented AF in 28.2 of the patients initially enrolled in the IABP SHOCK II trial. There were no significant differences in mortality rates at 30 days and 12 months between patients with and without AF. Likewise the rates of recurrent myocardial infarction repeat revascularization and stroke did not differ between groups. Furthermore there was no interaction of intra aortic balloon counter pulsation IABP and no IABP in patients with or without AF with respect to clinical outcome at 30 days and 12 months. Therefore it was inferred that AF is not associated with clinical outcome at 30 days and 12 months in CS complicating AMI.